GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (SHSE:688331) » Definitions » Accumulated Depreciation

RemeGen Co (SHSE:688331) Accumulated Depreciation : ¥-500 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is RemeGen Co Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

RemeGen Co's quarterly accumulated depreciation declined from Dec. 2022 (¥-328 Mil) to Jun. 2023 (¥0 Mil) but then increased from Jun. 2023 (¥0 Mil) to Dec. 2023 (¥-500 Mil).

RemeGen Co's annual accumulated depreciation increased from Dec. 2021 (¥-214 Mil) to Dec. 2022 (¥-328 Mil) and increased from Dec. 2022 (¥-328 Mil) to Dec. 2023 (¥-500 Mil).


RemeGen Co Accumulated Depreciation Historical Data

The historical data trend for RemeGen Co's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Accumulated Depreciation Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated Depreciation
Get a 7-Day Free Trial -102.47 -149.72 -214.20 -327.98 -500.08

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -214.20 - -327.98 - -500.08

RemeGen Co Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.


RemeGen Co Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co Headlines

No Headlines